Dr Reddy's Laboratories Shares Outstanding 2010-2024 | RDY
Dr Reddy's Laboratories shares outstanding history from 2010 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
- Dr Reddy's Laboratories shares outstanding for the quarter ending September 30, 2024 were 4.170B, a 400.52% increase year-over-year.
- Dr Reddy's Laboratories 2024 shares outstanding were 0.834B, a 0.19% increase from 2023.
- Dr Reddy's Laboratories 2023 shares outstanding were 0.832B, a 0.03% increase from 2022.
- Dr Reddy's Laboratories 2022 shares outstanding were 0.832B, a 0.01% increase from 2021.
Dr Reddy's Laboratories Annual Shares Outstanding
(Millions of Shares) |
| 2024 |
834 |
| 2023 |
832 |
| 2022 |
832 |
| 2021 |
832 |
| 2020 |
830 |
| 2019 |
831 |
| 2018 |
831 |
| 2017 |
835 |
| 2016 |
855 |
| 2015 |
852 |
| 2014 |
855 |
| 2013 |
856 |
| 2012 |
878 |
| 2011 |
827 |
| 2010 |
1,200 |
| 2009 |
850 |
Dr Reddy's Laboratories Quarterly Shares Outstanding
(Millions of Shares) |
| 2024-09-30 |
4,170 |
| 2024-06-30 |
835 |
| 2024-03-31 |
834 |
| 2023-12-31 |
834 |
| 2023-09-30 |
833 |
| 2023-06-30 |
855 |
| 2023-03-31 |
832 |
| 2022-12-31 |
832 |
| 2022-09-30 |
832 |
| 2022-06-30 |
833 |
| 2022-03-31 |
832 |
| 2021-12-31 |
830 |
| 2021-09-30 |
832 |
| 2021-06-30 |
837 |
| 2021-03-31 |
832 |
| 2020-12-31 |
847 |
| 2020-09-30 |
832 |
| 2020-06-30 |
837 |
| 2020-03-31 |
830 |
| 2019-12-31 |
828 |
| 2019-09-30 |
830 |
| 2019-06-30 |
828 |
| 2019-03-31 |
831 |
| 2018-12-31 |
831 |
| 2018-09-30 |
830 |
| 2018-06-30 |
838 |
| 2018-03-31 |
831 |
| 2017-12-31 |
829 |
| 2017-09-30 |
829 |
| 2017-06-30 |
750 |
| 2017-03-31 |
835 |
| 2016-12-31 |
830 |
| 2016-09-30 |
831 |
| 2016-06-30 |
864 |
| 2016-03-31 |
855 |
| 2015-12-31 |
855 |
| 2015-09-30 |
855 |
| 2015-06-30 |
845 |
| 2015-03-31 |
847 |
| 2014-12-31 |
858 |
| 2014-09-30 |
861 |
| 2014-06-30 |
852 |
| 2014-03-31 |
851 |
| 2013-12-31 |
847 |
| 2013-09-30 |
846 |
| 2013-06-30 |
763 |
| 2013-03-31 |
875 |
| 2012-12-31 |
863 |
| 2012-09-30 |
770 |
| 2012-06-30 |
750 |
| 2012-03-31 |
850 |
| 2011-12-31 |
808 |
| 2011-09-30 |
788 |
| 2011-06-30 |
843 |
| 2011-03-31 |
938 |
| 2010-12-31 |
763 |
| 2010-09-30 |
800 |
| 2010-06-30 |
750 |
| 2010-03-31 |
925 |
| 2009-12-31 |
800 |
| 2009-09-30 |
750 |
| 2009-06-30 |
845 |
| 2009-03-31 |
873 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$12.621B |
$3.350B |
|
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
|
